Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT.

Sredni ST, Patel K, D'Almeida Costa F, de Fátima Bonaldo M, Tomita T.

J Neurooncol. 2014 May;118(1):201-3. doi: 10.1007/s11060-014-1406-5. Epub 2014 Feb 27. No abstract available.

PMID:
24574049
2.

A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.

Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Goldman S, Geyer JR, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ.

J Neurooncol. 2013 Sep;114(2):173-9. doi: 10.1007/s11060-013-1166-7. Epub 2013 Jul 9.

3.

ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.

Wang H, Yang Q, Fu Z, Zuo D, Hua Y, Cai Z.

Cancer Invest. 2014 Dec;32(10):533-42. doi: 10.3109/07357907.2014.964409. Epub 2014 Oct 27. Review.

PMID:
25347730
4.

Afatinib, a lung cancer inhibitor of ErbB family.

de Antonellis P.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Jun;387(6):503-4. doi: 10.1007/s00210-014-0980-6. Epub 2014 Apr 13. No abstract available.

PMID:
24728512
5.

ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.

Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW.

Clin Cancer Res. 2002 Oct;8(10):3054-64.

6.

Perspectives in central nervous system malignancies.

Stummer W.

IDrugs. 2006 Jun;9(6):412-4. No abstract available.

PMID:
16752310
7.

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.

Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D.

Clin Cancer Res. 2010 Feb 15;16(4):1159-69. doi: 10.1158/1078-0432.CCR-09-2353. Epub 2010 Feb 9.

8.

Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?

Cappuzzo F.

J Natl Cancer Inst. 2005 Jun 15;97(12):868-9. No abstract available.

PMID:
15956643
9.

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.

Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820. Epub 2012 Jan 16.

10.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.

11.

Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.

Spector N.

Clin Breast Cancer. 2008 Mar;8 Suppl 3:S94-9. Review.

PMID:
18777948
12.

Cediranib: a VEGF receptor tyrosine kinase inhibitor.

Sahade M, Caparelli F, Hoff PM.

Future Oncol. 2012 Jul;8(7):775-81. doi: 10.2217/fon.12.73. Review.

PMID:
22830398
13.

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

Chen FL, Xia W, Spector NL.

Clin Cancer Res. 2008 Nov 1;14(21):6730-4. doi: 10.1158/1078-0432.CCR-08-0581. Review.

14.

Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.

Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK.

Breast Cancer Res Treat. 2006 Jan;95(1):17-27.

15.

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T.

Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14.

16.

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.

Oncogene. 2002 Sep 12;21(41):6255-63.

17.

Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.

Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.

Mol Pharmacol. 2008 Feb;73(2):338-48. Epub 2007 Nov 1.

18.

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A.

J Cell Physiol. 2011 Sep;226(9):2378-90. doi: 10.1002/jcp.22574.

PMID:
21660961
19.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

20.

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE.

Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8. Epub 2003 Jul 9.

Supplemental Content

Support Center